These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 25424123

  • 1. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
    Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA.
    Radiat Oncol; 2014 Nov 26; 9():245. PubMed ID: 25424123
    [Abstract] [Full Text] [Related]

  • 2. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.
    Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):554-61. PubMed ID: 23561650
    [Abstract] [Full Text] [Related]

  • 3. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
    Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY.
    Radiat Oncol; 2013 Jul 08; 8():170. PubMed ID: 23835115
    [Abstract] [Full Text] [Related]

  • 4. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY.
    Int J Radiat Oncol Biol Phys; 2013 Oct 01; 87(2):275-81. PubMed ID: 23886418
    [Abstract] [Full Text] [Related]

  • 5. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA.
    Int J Radiat Oncol Biol Phys; 2013 Jul 15; 86(4):721-8. PubMed ID: 23664325
    [Abstract] [Full Text] [Related]

  • 6. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.
    Cancer; 2013 Feb 01; 119(3):681-90. PubMed ID: 22893254
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
    Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE.
    Eur Urol Oncol; 2018 Sep 01; 1(4):276-282. PubMed ID: 31100248
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.
    Int J Radiat Oncol Biol Phys; 2012 Sep 01; 84(1):112-8. PubMed ID: 22300563
    [Abstract] [Full Text] [Related]

  • 12. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
    Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y.
    Eur Urol; 2013 Jul 01; 64(1):19-25. PubMed ID: 22901983
    [Abstract] [Full Text] [Related]

  • 13. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G, Neumann K, Budach V, Wiegel T, Hoecht S, Gollrad J.
    Strahlenther Onkol; 2018 Apr 01; 194(4):325-332. PubMed ID: 29255924
    [Abstract] [Full Text] [Related]

  • 14. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
    Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL.
    World J Urol; 2016 Dec 01; 34(12):1611-1619. PubMed ID: 27084777
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
    D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH.
    J Natl Cancer Inst; 2004 Apr 07; 96(7):509-15. PubMed ID: 15069112
    [Abstract] [Full Text] [Related]

  • 19. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.
    Radiother Oncol; 2019 Mar 07; 132():211-217. PubMed ID: 30389241
    [Abstract] [Full Text] [Related]

  • 20. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
    Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY.
    Cancer; 2013 Sep 15; 119(18):3287-94. PubMed ID: 23821578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.